Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb single-arm study of sacituzumab govitecan in previously treated metastatic triple-negative breast cancer in China
CTR20200914Phase 2Active
- Sponsor
- Everest Medicines
- Start
- Nov 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Everest Medicines. Started Nov 2020; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20200914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200914.